Speculating Cogstate won't be listed very long... Releasing...

Speculating Cogstate won't be listed very long... Releasing themselves from Eisai to give flexibility to diversify income from august. Based on this announcement the results are rolling in, guidance of all key elements are "from" so base is in. Buyback tone has changed year-on-year its back on disappoint its not being used NOW given the backdrop and being highly earnings accretive. Business is $USD also great given US backdrop currently. Cash balance sheet too.
The other "partners" of Dassault are large companies snowflake mkt. $40bn even click therapeutics VC backed has raised since founding $926m no known profits to either. Cogstate at current mkt cap, clean balance sheet, shares is $AUS, buyback backstop ready, spreading wings with revenue also Large pharma dementia treatments hasn't reached peak spending. Spend of $2.2bn in 2020 on latest forecast to $22bn in 2030. Cogstate would fit very nicely into Dassault product suite with profits from day one even with a healthy takeover premium.